Diversified Healthcare Trust Earnings Call Transcripts
Fiscal Year 2026
-
Q3 Normalized FFO was $0.13 per share and Adjusted EBITDAre rose 28.4% YoY, supported by SHOP NOI growth of 50.4%. FY2026 SHOP NOI guidance rose, while recurring CapEx guidance declined by $10 million at midpoint.
-
Second quarter results exceeded expectations, with strong SHOP segment growth and margin expansion offsetting slower occupancy ramp-up. Guidance was reaffirmed, with continued focus on expense control, capital redeployment, and organic earnings growth.
-
A $6.2B healthcare portfolio is focusing on internal growth, operational improvements, and capital recycling, with SHOP assets driving future NOI. Leverage has been reduced, guidance raised, and management sees strong demographic demand and further upside despite recent stock gains.
-
First quarter results exceeded expectations with strong NOI and margin growth, driven by operational improvements and disciplined capital allocation. Guidance for 2026 was reaffirmed, with continued momentum expected in SHOP and medical office segments.
Fiscal Year 2025
-
Delivered strong Q4 and full-year results with significant NOI and margin growth, reduced leverage, and robust operational execution. 2026 guidance anticipates further NOI and margin expansion, supported by disciplined capital allocation and favorable industry trends.
-
Q3 revenue rose 4% year-over-year to $388.7M, with SHOP segment NOI up 7.8% and occupancy at 81.5%. Transition of 116 communities to new operators is nearly complete, supporting margin and cash flow growth. No debt maturities until 2028 after 2026 bond repayment.
-
Second quarter 2025 results beat expectations with strong SHOP segment growth, higher margins, and improved occupancy. Asset sales and refinancing support deleveraging, while 2025 guidance for SHOP NOI and CapEx was raised and tightened, respectively.
-
Portfolio repositioning and capital investments are driving strong NOI and occupancy growth, especially in the SHOP segment. Dispositions of non-core assets and refinancing have improved leverage, with further asset sales and expense controls planned. Demographic tailwinds and limited new supply support continued upside.
-
First quarter 2025 saw 4% revenue growth and strong SHOP segment performance, with significant asset sales and refinancing efforts reducing leverage. 2025 guidance for SHOP NOI and CapEx was reaffirmed, with further debt reduction expected from pending dispositions.
Fiscal Year 2024
-
Q4 2024 revenue rose 5% year-over-year to $379.6M, with SHOP segment occupancy reaching 80% and NOI up 56%. Asset sales and new financings are set to address 2025 and 2026 debt maturities, while 2025 CapEx is projected to decline 16% from 2024.
-
Q3 saw strong year-over-year SHOP NOI growth but sequential declines due to higher costs and slow occupancy gains. Asset sales and refinancing are underway to improve margins and reduce leverage, with full-year guidance lowered due to hurricane impacts and underperformance.
-
Q2 results exceeded expectations with strong SHOP and medical office performance, driving NOI and FFO growth. Portfolio optimization, asset sales, and major renovations are enhancing returns, while 2024 guidance for SHOP NOI and CapEx was reaffirmed or reduced.
-
The conference highlighted strong demographic and market tailwinds for the SHOP portfolio, ongoing asset repositioning, and robust rent growth in medical office and life science segments. Capital structure remains flexible, with new financings and asset sales supporting future growth.